Referral decisions based on a pre-hospital HEART score in suspected non-ST-elevation acute coronary syndrome: final results of the FamouS Triage study. Issue 2 (25th November 2021)

• Record Type: Journal Article
• Authors: Tolsma, Rudolf T; Fokkert, Marion J; van Dongen, Dominique N; Badings, Erik A; van der Sluis, Aize; Slingerland, Robbert J; van 't Riet, Esther; Ottervanger, Jan Paul; van 't Hof, Arnoud W J
• Is Part Of: European heart journal. Volume 11:Issue 2(2022)
• Page Start: 160
• Page End: 169
• Publication Date: 2021-11-25
• Subjects: Pre-hospital -- Triage -- Acute-Coronary-Syndrome -- HEART score; 616.1205
• DOI: 10.1093/ehjacc/zuab109
• Languages: English
• ISSNs: 2048-8726

Abstract

Abstract: Aims: Although pre-hospital risk stratification of patients with suspected non-ST-elevation acute coronary syndrome (NSTE-ACS) by ambulance paramedics is feasible, it has not been investigated in daily practice whether referral decisions based on this risk stratification is safe and does not increase major adverse cardiac events (MACE). In Phase III of the FamouS Triage study, it was investigated whether referral decisions by ambulance paramedics based on a pre-hospital HEART score, is non-inferior to routine management. Methods and results: FamouS Triage Phase III is a non-inferiority study, comparing the occurrence of MACE before (Phase II) and after (Phase III) implementation of referral decisions based on a pre-hospital HEART score. In Phase II, all patients were risk-stratified and referred to the hospital; in Phase III, low-risk patients (HEART score ≤ 3) were not referred. Primary endpoint was MACE (acute coronary syndrome, revascularization, or death) within 45 days. A total of 1236 patients were included. Mean age was 63 years, 43% were female, 700 patients were included in the second phase and 536 in the third phase in which 149 low-risk patients (28%) were not transferred to the hospital. Occurrence of 45 days MACE was 16.6% in Phase II and 15.7% in Phase III ( P = 0.67). Percentage MACE in low-risk patients was 2.9% in Phase II and 1.3% in Phase III. After adjustments for differences in baseline variables, the hazard ratio of 45 days MACE in Phase III was 0.88 (95% confidence interval 0.63–1.25) as compared to Phase II. Conclusion: Pre-hospital risk stratification of patients with suspected NSTE-ACS, avoiding hospitalization of a substantial number of low-risk patients, seems feasible and non-inferior to transferring all patients to the hospital. Graphical Abstract: